ライフサイエンスコーパス: inhalational

1 phage administration was more effective than inhalational administration, suggesting that circulating

2 a progressive shift to using more expensive inhalational agents and total intravenous anesthesia in

3 rhaps even less effective, than titration of inhalational agents using end tidal anesthetic concentra

4 Among the inhalational agents, usage costs of sevoflurane and desf

5 Recording solutions were equilibrated with inhalational anaesthetic vapour delivered from a calibra

6 entobarbital, midazolam, propofol, ketamine, inhalational anaesthetics (isoflurane, desflurane), anti

7 ble individuals on exposure to commonly used inhalational anaesthetics and depolarising muscle relaxa

8 The effects of the inhalational anaesthetics halothane and isoflurane on th

9 olved in the mechanism of action of general (inhalational) anaesthetics.

10 s encountered in vivo, as well as in vivo in inhalational and cutaneous mouse models of B. anthracis

11 which can help prioritize efforts to reduce inhalational and dermal exposures.

12 s in acute adaptive immune responses between inhalational and dermal infection with F. tularensis LVS

13 me binding site mediates recognition of both inhalational and injectable anesthetics.

14 The comparison of inhalational and intravenous anaesthesia has been the su

15 Bispectral index monitoring during inhalational anesthesia adds to the cost without providi

16 thesia offers a physiological advantage over inhalational anesthesia for thoracic surgery remain inco

17 cause temporary amnesia, yet the effects of inhalational anesthesia on human emotional memory proces

18 ed with lower incidence of laryngospasm than inhalational anesthesia.

19 esthetized with a virtually nondefluorinated inhalational anesthetic (desflurane) or with a nonfluori

20 advantages for any of the commonly available inhalational anesthetic agents and each can be used for

21 Inhalational anesthetic agents have also been shown to r

22 Xenon and dichloromethane are inhalational anesthetic agents whose binding to myoglobi

23 ative, analgesics, benzodiazepines, opioids, inhalational anesthetic agents, nitrous oxide, ketamine,

24 ous oxide (N2O, laughing gas), a widely used inhalational anesthetic and drug of abuse.

25 To identify inhalational anesthetic binding domains in a ligand-gate

26 To determine inhalational anesthetic binding domains on a ligand-gate

27 during surgery (derived from mean end-tidal inhalational anesthetic concentrations).

28 Inhalational anesthetic dose increase and reduced risk o

29 High inhalational anesthetic dose of 1.20 (1.13-1.30) (median

30 We sought to determine the effect of inhalational anesthetic dose on risk of severe postopera

31 Additionally, high inhalational anesthetic dose was associated with lower 3

32 Intraoperative use of higher inhalational anesthetic doses is strongly associated wit

33 can be utilized to probe the binding of the inhalational anesthetic halothane to an anesthetic-bindi

34 amuscular sedative was given, followed by an inhalational anesthetic induction and mechanical ventila

35 iments were performed with the commonly used inhalational anesthetic sevoflurane.

36 ectroscopic probe to study the binding of an inhalational anesthetic to a model membrane protein.

37 Clinical concentrations of the inhalational anesthetic, halothane (1 rat MAC, 1.2 vol.%

38 Isoflurane, the most widely used inhalational anesthetic, releases inorganic fluoride dur

39 We now report that inhalational anesthetics affect gene expression of nitri

40 ersing the effects of some anesthetic drugs (inhalational anesthetics and muscle relaxants) are descr

41 This is a novel interaction between inhalational anesthetics and the NO signaling pathway an

42 Inhalational anesthetics are bronchodilators with immuno

43 They also received inhalational anesthetics because of refractory bronchoco

44 Postconditioning with inhalational anesthetics can reduce ischemia-reperfusion

45 At surgical depths of anesthesia, inhalational anesthetics cause a loss of motor response

46 These data indicate that inhalational anesthetics cause activation of RTN neurons

47 Currently, it is thought that inhalational anesthetics cause anesthesia by binding to

48 e that clinically relevant concentrations of inhalational anesthetics dose-dependently and specifical

49 Median effective dose equivalent of inhalational anesthetics during surgery (derived from me

50 Inhalational anesthetics have been shown to inhibit the

51 sting differences in the binding domains for inhalational anesthetics in the nAChR.

52 sthesia is indicated for procedures in which inhalational anesthetics may not be safely or effectivel

53 w that clinically relevant concentrations of inhalational anesthetics modulate neuronal Ih and the co

54 A better understanding of the effect of inhalational anesthetics on fetal cardiac function and s

55 ulate based on these data that sedation with inhalational anesthetics outside of the operating room m

56 The molecular pharmacology of inhalational anesthetics remains poorly understood.

57 in experimental traumatic brain injury with inhalational anesthetics, these results indicate that th

58 the native RTN current (i.e., suppression by inhalational anesthetics, weak rectification, inhibition

59 ures incompatible with effective delivery of inhalational anesthetics.

60 lar concentration is central to the study of inhalational anesthetics.

61 ose receptors is less certain in the case of inhalational anesthetics.

62 the PDZ domain as a new molecular target for inhalational anesthetics.

63 Administration of inhalational anesthetics.

64 Prevention of inhalational anthrax after Bacillus anthracis spore expo

65 ber 19 and October 26, there were 5 cases of inhalational anthrax among postal workers who were emplo

66 py appears to have slowed the progression of inhalational anthrax and has resulted to date in surviva

67 otic prophylaxis required to protect against inhalational anthrax and may impact public health manage

68 osed to prophylaxis, could effectively treat inhalational anthrax and prevent disease caused by the g

69 d cough do not reliably discriminate between inhalational anthrax and viral respiratory tract infecti

70 The cases of 2 postal workers who died of inhalational anthrax are reported here.

71 conduct credible human risk assessments for inhalational anthrax associated with exposure to a low n

72 es are decisive events in the progression of inhalational anthrax because they initiate germination a

73 Also, rabbits that were protected from inhalational anthrax by administration of ETI-204 develo

74 atocrit were more frequently recorded in the inhalational anthrax cases than in either the community-

75 Inhalational anthrax caused by Bacillus anthracis is ass

76 of patients who died of bioterrorism-related inhalational anthrax confirmed the route of infection.

77 This study demonstrated that the course of inhalational anthrax disease and the resulting pathology

78 ant importance to reassess the mechanisms of inhalational anthrax dissemination, since it is this for

79 Mortality from inhalational anthrax during the 2001 U.S. attack was sub

80 g the recent bioterrorism-related outbreaks, inhalational anthrax had a 45% mortality in spite of app

81 Inhalational anthrax has characteristic clinical feature

82 had been mailed to a US senator, 5 cases of inhalational anthrax have occurred among postal workers

83 adenopathy led to a presumptive diagnosis of inhalational anthrax in both cases.

84 is capsule and toxins in the pathogenesis of inhalational anthrax in rabbits by comparing infection w

85 of rPA provides complete protection against inhalational anthrax in rabbits.

86 identification of patients with presumptive inhalational anthrax in the setting of a large-scale ant

87 l history, pathophysiology, and pathology of inhalational anthrax in this animal model following nose

88 ed attenuated virulence in a murine model of inhalational anthrax infection.

89 udies aiming to understand events initiating inhalational anthrax infections.

90 The rabbit model of inhalational anthrax is an important tool in the assessm

91 Inhalational anthrax is caused by inhalation of Bacillus

92 Inhalational anthrax is caused by the sporulating bacter

93 's high index of suspicion, the diagnosis of inhalational anthrax is difficult during nonspecific pro

94 Inhalational anthrax is initiated by the entry of Bacill

95 ed public health responses to an outbreak of inhalational anthrax is the optimum duration of antibiot

96 advances in supportive care, fulminant-phase inhalational anthrax is usually fatal.

97 rax attack, mass screening to identify early inhalational anthrax may improve both the management of

98 istorical data sets from West Nile virus and inhalational anthrax outbreaks.

99 th authorities investigated 11 patients with inhalational anthrax related to a bioterrorism attack in

100 scribe the 11th case of bioterrorism-related inhalational anthrax reported in the United States.

101 has been proposed that the dissemination of inhalational anthrax required spores to be transported f

102 Postexposure prophylaxis of inhalational anthrax requires prolonged antibiotic thera

103 CT) findings in two patients with documented inhalational anthrax resulting from bioterrorism exposur

104 is developed to analyze the transmission of inhalational anthrax through the postal system by cross-

105 CR and MCR model appeared to describe rabbit inhalational anthrax well.

106 competing risks (CR) computational model of inhalational anthrax where data was collected from NZW r

107 Aerosol challenge of guinea pigs resulted in inhalational anthrax with death occurring between 46 and

108 g was 100% sensitive (95% CI 84.6-100.0) for inhalational anthrax, 71.8% specific (64.8-78.1) compare

109 osure to Bacillus anthracis spores initiates inhalational anthrax, a life-threatening infection.

110 of the central stages in the progression of inhalational anthrax, and it is commonly believed that t

111 are likely the first immune cells exposed to inhalational anthrax, and the interferon (IFN) response

112 R/MCR model with other computation models of inhalational anthrax, and using the resulting informatio

113 During inhalational anthrax, Bacillus anthracis survives and re

114 The etiologic agent of inhalational anthrax, Bacillus anthracis, produces virul

115 60 days of antibiotic prophylaxis to prevent inhalational anthrax, but adherence to this regimen was

116 York City hospital employee developed fatal inhalational anthrax, but with an unknown source of anth

117 Bacillus anthracis, the causative agent of inhalational anthrax, enters a host through the pulmonar

118 In contrast to events in experimental inhalational anthrax, spore germination in these cutaneo

119 significantly attenuated in a mouse model of inhalational anthrax, suggesting that the microarray dat

120 In the treatment of inhalational anthrax, the prolonged course of antibiotic

121 To identify clinical characteristics of inhalational anthrax, we compared 47 historical cases (i

122 Although several factors contribute to inhalational anthrax, we hypothesized that unimpeded inf

123 teritis; however, some recent isolates cause inhalational anthrax-like diseases and death.

124 use aerosol challenge model for the study of inhalational anthrax.

125 one and completely protected animals against inhalational anthrax.

126 urrently no approved effective treatment for inhalational anthrax.

127 tive therapy for prevention and treatment of inhalational anthrax.

128 ts toward identifying clinical predictors of inhalational anthrax.

129 s an endospore-forming bacterium that causes inhalational anthrax.

130 The cause of death was inhalational anthrax.

131 tes, but tragically some individuals died of inhalational anthrax.

132 as been described as the classic pattern for inhalational anthrax.

133 Bacillus anthracis can cause inhalational anthrax.

134 vivo NK cell depletion in a murine model of inhalational anthrax.

135 ignificantly attenuated in a murine model of inhalational anthrax.

136 icrobial activity, we used a murine model of inhalational anthrax.

137 ival in rabbits and monkeys with symptomatic inhalational anthrax.

138 des unique insight into host defense against inhalational anthrax; these data also support the notion

139 Inhalational antibiotics reduce the bacterial burden ass

140 Both viral infection and inhalational antigen challenge cause M(2)R dysfunction,

141 Airway eosinophils, recovered after inhalational antigen challenge in sensitized mice, expre

142 ent mice, airway eosinophils recovered after inhalational antigen challenge stimulated antigen-specif

143 We examined in vivo whether pre-existing inhalational antigen tolerance could be overcome by acti

144 Inhalational antigen tolerance typically protects agains

145 ice with lethal disseminated candidiasis and inhalational aspergillosis.

146 nge, the lungs of C57BL/6 mice (resistant to inhalational B. anthracis infection) had significantly h

147 Murine inhalational B. anthracis infections have two portals of

148 for the high mortality rates associated with inhalational Bacillus anthracis infection.

149 s applied to serum from rhesus macaques with inhalational botulism following exposure to BoNT/B, show

150 erize the rhesus macaque (RM) as a model for inhalational brucellosis in support of the U.S. Food and

151 ort the use of the RM as an animal model for inhalational brucellosis to evaluate the efficacy of nov

152 clinical presentation and pathophysiology of inhalational brucellosis, Balb/c mice were challenged wi

153 l for the evaluation of therapeutics against inhalational brucellosis.

154 induce a humoral immune response to a single inhalational challenge to HDM.

155 Capsaicin inhalational challenge was performed, and cough response

156 complete or nearly complete protection from inhalational challenge with 100% lethal doses of B. mall

157 and Hcp1, 100% of the mice survived a lethal inhalational challenge with B. pseudomallei Remarkably,

158 resulted in enhanced levels of IL-17A after inhalational challenge with HDM.

159 Inhalational challenges to histamine and methacholine (M

160 second only to carbon monoxide as a cause of inhalational deaths.

161 nited States in 2001 resulted in 11 cases of inhalational disease, with an attendant mortality rate o

162 o were referred for evaluation, a history of inhalational exposure to a 2003 sulfur-mine fire in Iraq

163 developed a model of airway inflammation and inhalational exposure to investigate regulatory pathways

164 a in female Fischer 344 rats after nose-only inhalational exposure to lethal doses of aerosolized Fra

165 Continuous inhalational exposure to OVA (6 or 11 weeks) resulted in

166 Discontinuous inhalational exposure to OVA (6 weeks) produced airway i

167 In humans, inhalational exposure to particulate air pollutants decr

168 hiolitis, which was possibly associated with inhalational exposure, in 38 soldiers.

169 e cause such as collagen vascular disease or inhalational exposure.

170 These results suggest that occupational inhalational exposures are independently associated with

171 soldiers from Fort Campbell, Kentucky, with inhalational exposures during service in Iraq and Afghan

172 ts should be alert to avoid excessively high inhalational flow.

173 The inhalational form of anthrax is the most severe and is a

174 of IL-17A and IFN-gamma in the lungs during inhalational Francisella infection and that these cytoki

175 We hypothesized that nitrous oxide, an inhalational general anesthetic and N-methyl-D-aspartate

176 We have previously shown that recognition of inhalational general anesthetics by the model protein ap

177 Inhalational general anesthetics have recently been show

178 + channels strongly suggest that halogenated inhalational general anesthetics interact with gates and

179 coccus neoformans H99 infection by comparing inhalational H99 infections in wild-type BALB/c and IL-4

180 phics of research studies with intranasal or inhalational ICS.

181 olam formulated in flavoured syrups, and the inhalational induction of anaesthesia may be accomplishe

182 on has become the most widely cited model of inhalational infection as well as the focus of the major

183 that bacterial dissemination patterns during inhalational infection may be more similar to the cutane

184 compared in both the murine intravenous and inhalational infection models, there were significant di

185 es an attractive strategy to protect against inhalational infection with virulent B. melitensis.

186 Using a clinically relevant mouse model of inhalational infection with virulent C. neoformans H99,

187 oning, fire-related toxic gas exposures, and inhalational injuries.

188 In a sulfur dioxide (SO2) inhalational injury model, bromodeoxyuridine (BrdU) inco

189 but it may not have a role in patients with inhalational injury.

190 ly an adult disease occurring after years of inhalational insults to the lungs, pinpointing abnormali

191 ly used volatile anesthetic, and is used for inhalational long-term sedation in critically ill patien

192 results define early events occurring in an inhalational macaque monkeypox infection model, supporti

193 rranted to confirm the effectiveness of this inhalational method.

194 t than the control strains in both the mouse inhalational model and the rabbit meningitis model.

195 e and the reconstituted strain in the murine inhalational model, and it also had significantly impair

196 measured by cumulative survival in the mouse inhalational model.

197 measured by cumulative survival in the mouse inhalational model.

198 Here, the early pathogenic events of inhalational monkeypox infection in NHPs were characteri

199 Inhalational MtbDeltasigH, a stress-response-attenuated

200 acute respiratory distress syndrome (ARDS), inhalational NO has proved to be useful.

201 whatever the route of infection (cutaneous, inhalational, or digestive).

202 Inhalational plague in the cynomolgus macaque inoculated

203 Inhalational pneumonic tularemia, caused by Francisella

204 (NASBA) method was investigated by use of an inhalational rat model of IPA.

205 a civilian or military population through an inhalational route of exposure and aerosol is considered

206 administration of drugs to the lung via the inhalational route provides for high concentrations at t

207 Comparing disease manifestations, inhalational survivors reported significantly lower over

208 solution of AAD and the development of local inhalational tolerance (LIT).

209 ent resolution with the development of local inhalational tolerance (LIT).

210 appaB activation orchestrate the breaking of inhalational tolerance and allergic antigen sensitizatio

211 Inhalational tolerance induced by continuous OVA exposur

212 aled OVA on Day 30 in an attempt to overcome inhalational tolerance.

213 ment strategies augment the response to this inhalational vasodilator.

214 at a delayed HMBPP/IL-2 administration after inhalational Yersinia pestis infection induced marked ex